Back to top
more

Madrigal Pharmaceuticals (MDGL)

(Delayed Data from NSDQ)

$193.33 USD

193.33
453,242

-1.05 (-0.54%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $192.63 -0.70 (-0.36%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zacks Investment Ideas feature highlights: SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals

by Zacks Equity Research

SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals have been highlighted in this Investment Ideas article.

Andrew Rocco headshot

2 Top Biotech Buyout Candidates

by Andrew Rocco

The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities

Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH

by Zacks Equity Research

Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.

Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals

by Zacks Equity Research

Ionis (IONS) reports positive phase II study results, which show that treatment with ION224 has the potential to improve MASH and prevent its progression to more severe stages.

Akero (AKRO) Slumps 63% on Mixed Results From NASH Study

by Zacks Equity Research

Data from a mid-stage study shows that Akero Therapeutics' (AKRO) lead candidate failed to achieve statistical significance in its primary endpoint of fibrosis improvement in cirrhotic NASH patients.

Madrigal (MDGL) to Raise Capital Via Public Offering of $500M

by Zacks Equity Research

Madrigal (MDGL) is raising funds through a public offering of 1.25 million shares of its common stock to use in commercial activities in the preparation of a potential launch of resmetirom in the United States.

Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA

by Zacks Equity Research

Madrigal (MDGL) gains as new drug application for resmeritom to treat nonalcoholic steatohepatitis gets accepted by the FDA in the United States.

Intercept (ICPT) NDA for NASH Treatment Gets CRL From FDA

by Zacks Equity Research

Intercept's (ICPT) NDA for obeticholic acid (OCA) gets a complete response letter (CRL) from the FDA for treating pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH).

Here's Why Hepion Pharma (HEPA) is Up More Than 80% in Two Days

by Zacks Equity Research

Hepion Pharmaceuticals' (HEPA) lead pipeline candidate, rencofilstat, demonstrates improvements in physiologic liver function and key NASH biomarkers in the phase II ALTITUDE-NASH study in advanced NASH patients.

Intercept (ICPT) NASH Treatment Fails to Get GIDAC Recommendation

by Zacks Equity Research

Intercept's (ICPT) NASH treatment does not succeed in getting GIDAC's recommendation for an approval. The committee recommends deferring approval until clinical data from another study is available.

Intercept (ICPT) Down Ahead of GIDAC Meeting for NASH Treatment

by Zacks Equity Research

Intercept (ICPT) falls 14.7% a couple of days before the scheduled GIDAC meeting to review its NASH treatment on concerns of adverse events.

Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study

by Zacks Equity Research

A mid-stage study data shows that Viking Therapeutics' (VKTX) VK2809 achieved reductions in liver fat content in patients with biopsy-confirmed NASH, following 12-weeks of treatment.

Intercept (ICPT) Gains 26.2% YTD: What's in Store?

by Zacks Equity Research

Intercept (ICPT) has been having a good run in the year so far, but investors are wary ahead of the upcoming advisory meeting by the FDA's Gastrointestinal Drugs Advisory Committee to review its NDA seeking approval of OCA in steatohepatitis (NASH).

Madrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy Tag

by Zacks Equity Research

Madrigal Pharmaceuticals (MDGL) gains on receiving Breakthrough Therapy designation from the FDA for resmetirom.

Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates

by Zacks Equity Research

Pipelines updates from Madrigal (MDGL) and Vaxcyte, (PCVX) are the key highlights of the biotech sector.

89bio (ETNB) Up 25% on Upbeat Data From Mid-Stage NASH Study

by Zacks Equity Research

Data from a phase IIb study showed that treatment with 89bio's (ETNB) lead candidate improved fibrosis improved fibrosis at 3.5 times the rate of the placebo without worsening NASH.

Intercept (ICPT) Stock Down on FDA Committee Update on NDA

by Zacks Equity Research

Intercept (ICPT) declines on news of a GIDAC meeting to discuss the NDA for the OCA for NASH in May.

Heres Why Intercept (ICPT) Stock is Up 28.7% in 3 Months

by Zacks Equity Research

Intercept (ICPT) gains 28.7% in the past 3 months on NDA's acceptance for NASH treatment and Ocaliva's performance.

Andrew Rocco headshot

This "Golden" Technical Indicator is Triggering Across the Market

by Andrew Rocco

A Golden Cross is a simple, yet effective technical indicator. Andrew Rocco explains how to use it and relates it back to the current market.

Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA

by Zacks Equity Research

Intercept's (ICPT) new drug application (NDA) for obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis gets accepted by the regulatory body in the United States.

Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why

by Zacks Equity Research

Intercept (ICPT) gains 12% in the last six months on Ocaliva's positive performance and encouraging pipeline progress.

Chemomab (CMMB) Mid-Stage Study for NASH Meets Primary Goal

by Zacks Equity Research

Chemomab's (CMMB) phase II study evaluating CM-101 in NASH patients met its primary endpoint of safety and tolerability.

Ekta Bagri headshot

Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More

by Ekta Bagri

Pipeline updates from Madrigal (MDGL) and Entrada (TRDA) are the key highlights from the biotech sector during the past week.

Madrigal (MDGL) Soars as Resmetirom Meets Goal in NASH Study

by Zacks Equity Research

Madrigal's (MDGL) phase III MAESTRO-NASH study evaluating resmetirom for treating nonalcoholic steatohepatitis and liver fibrosis meets both primary endpoints. Stock rises.

Here's Why Madrigal (MDGL) is Poised for a Turnaround After Losing 14.9% in 4 Weeks

by Zacks Equity Research

Madrigal (MDGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.